Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MIMETAS logo — Human Tissue Models for Better Therapies

MIMETAS

Human Tissue Models for Better Therapies

Founded 2013 The Netherlands The Netherlands 99 employees Grant Total: $31.91M Biotechnology, Health Care +2

General Information

Company Name MIMETAS
Founded Year 2013
Location The Netherlands The Netherlands +3
Founders / Decision Makers
Team member Team member
Employees 99
Industries Biotechnology, Health Care, Information Technology +1
Funding Stage Grant
Social

Get notified when MIMETAS moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MIMETAS

MIMETAS, founded in 2013 and headquartered in The Netherlands, operates at the intersection of Biotechnology, Health Care, Information Technology, and VR/AR. The company is renowned for its slogan: Human Tissue Models for Better Therapies. MIMETAS specializes in developing cutting-edge, screenable 3D human disease models that are physiologically relevant. This innovation aids in forging strong drug development partnerships with global pharmaceutical giants, thereby facilitating the creation of groundbreaking therapies aimed at previously untreatable diseases.

The company's commitment to innovation is underscored by its successful acquisition of a €3.01M grant investment from the EASME - EU Executive Agency for SMEs as of 01 January 2019. This investment not only highlights investor confidence in their potential but also signifies a strategic step towards expansive growth in their specialized fields.

Taxonomy: Organ-on-a-Chip, 3D Human Disease Models, Predictive Toxicology, Microfluidics, Cell-based Assays, High-throughput Screening, Phenotypic Screening, Microphysiological Systems, Blood-brain Barrier Models, Liver Models, Kidney Models, 3D Cell Culture, Disease Modeling, Pharmaceutical Partnerships, Drug Development

Services & Products

CRO Services
Training
Product Development
AI/Automation
Disease Mechanism Understanding
Drug Efficacy and Safety Testing
Target Discovery and Validation
Compound Prioritization and Derisking

Target Customers

Pharmaceutical Companies Biotech Companies Academic Researchers Healthcare Researchers Regulatory Agencies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Jan 2019
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		11 Apr 2018
Series B •••••• - 05 Jan 2016
Series A •••••• 2
Investor
•••• •••• 		08 Oct 2014
Seed Round •••••• - 11 Sep 2014

MIMETAS Alternatives & Competitors

View All Alternatives
MIMETAS vs
Autolus Therapeutics
Autolus Therapeutics United Kingdom

Focused on the development of precisely targeted, controlled & highly active T cell therapies for ca...

Post Ipo Equity
763 employees
Biopharma, Biotechnology
Compare MIMETAS vs Autolus Therapeutics
MIMETAS vs
Horizon Discovery
Horizon Discovery United Kingdom

On the path from research to therapy – Inspired Cell Solutions

Acquired
92 employees
Compare MIMETAS vs Horizon Discovery
MIMETAS vs
Eigen Therapeutics
Eigen Therapeutics United States

We help targeted therapies hit their mark.

Seed
4 employees
Biotechnology, Life Sciences
Compare MIMETAS vs Eigen Therapeutics
View all alternatives

FAQ About MIMETAS

Human Tissue Models for Better Therapies
MIMETAS was founded in 2013.
MIMETAS is headquartered in The Netherlands.
MIMETAS operates in the following industries: Biotechnology, Health Care, Information Technology, VR/AR.
MIMETAS has approximately 99 employees.
MIMETAS has completed 5 funding rounds, raising a total of $31.91M. The latest funding stage is Grant.
MIMETAS offers: CRO Services, Training, Product Development, AI/Automation, Disease Mechanism Understanding, Drug Efficacy and Safety Testing, Target Discovery and Validation, Compound Prioritization and Derisking.
Top alternatives and competitors to MIMETAS include Autolus Therapeutics, Horizon Discovery, Eigen Therapeutics, Curi Bio, Celogics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MIMETAS and Autolus Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MIMETAS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy